• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

针对磷酸肌醇 3-激酶同工型特异性抑制的对接研究。

Docking studies on isoform-specific inhibition of phosphoinositide-3-kinases.

机构信息

College of Pharmacy, University of Nebraska Medical Center, 986025 Nebraska Medical Center, Omaha, Nebraska 68198-6025, USA.

出版信息

J Chem Inf Model. 2010 Oct 25;50(10):1887-98. doi: 10.1021/ci1002679.

DOI:10.1021/ci1002679
PMID:20866085
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4480772/
Abstract

Phosphatidylinositol 3-kinase α (PI3Kα) is a promising target for anticancer drug design. Oncogenic mutation H1047R in the catalytic domain is observed in many tumors and may enhance PI3Kα kinase activity by affecting loop confirmations as well as membrane binding. We applied docking methods to 33 PI3K inhibitors against the wild type (wt) PI3Kα, the H1047R mutant of PI3Kα and the γ isoform of PI3K (PI3Kγ). We also investigated the effect of protein flexibility on ligand binding by docking the same set of ligands to conformations of the wt and mutant PI3Kα generated by molecular dynamics simulations. Our data suggests that conformational differences in Gln859, Ser854, Tyr836, and Ser774 between the PI3Kα wt and H1047R mutant may be used to design ligands that are active against both the wt and H1047R mutant isoforms. Gln859, Ser854 and Ser774 may play critical roles in ligand binding to the α isoform H1047R mutant while formation of H-bonds with Ser806 of PI3Kγ may enhance γ-isoform-specific inhibition. In addition to H-bond interactions, structural and size differences in the activation and hydrophobic domains of PI3Kα, PI3Kγ, and the PI3Kα H1047R mutant could be exploited to direct the design of isoform- and/or mutant-specific PI3K inhibitors. Our data provide a reasonable explanation for the activity and selectivity of small molecular PI3K inhibitors and are in good agreement with available experimental and computational data.

摘要

磷脂酰肌醇 3-激酶α(PI3Kα)是一种很有前途的抗癌药物设计靶点。在许多肿瘤中观察到催化结构域中的致癌突变 H1047R,它可能通过影响环构象以及膜结合来增强 PI3Kα 激酶活性。我们应用对接方法对 33 种 PI3K 抑制剂进行了研究,这些抑制剂针对野生型(wt)PI3Kα、PI3Kα 的 H1047R 突变体和 PI3K 的 γ 同工型(PI3Kγ)。我们还通过对接分子动力学模拟生成的 wt 和突变 PI3Kα 构象中的同一组配体,研究了蛋白质柔性对配体结合的影响。我们的数据表明,wt 和 H1047R 突变体 PI3Kα 之间 Gln859、Ser854、Tyr836 和 Ser774 的构象差异可用于设计对 wt 和 H1047R 突变体同工型均具有活性的配体。Gln859、Ser854 和 Ser774 可能在配体与α同工型 H1047R 突变体的结合中发挥关键作用,而与 PI3Kγ 的 Ser806 形成氢键可能增强γ同工型特异性抑制。除了氢键相互作用外,PI3Kα、PI3Kγ 和 PI3Kα H1047R 突变体的激活和疏水区的结构和大小差异可用于指导同工型和/或突变体特异性 PI3K 抑制剂的设计。我们的数据为小分子 PI3K 抑制剂的活性和选择性提供了合理的解释,与现有实验和计算数据吻合良好。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e56d/4480772/e8f5d6cc0932/nihms-696565-f0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e56d/4480772/cf22b000ae59/nihms-696565-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e56d/4480772/9fe4dee34862/nihms-696565-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e56d/4480772/2be01a1110ff/nihms-696565-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e56d/4480772/3942fe502db2/nihms-696565-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e56d/4480772/5c01b801a575/nihms-696565-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e56d/4480772/44515176487b/nihms-696565-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e56d/4480772/88d5a6a107ec/nihms-696565-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e56d/4480772/2dfc64ac1202/nihms-696565-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e56d/4480772/0f86d5ba369e/nihms-696565-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e56d/4480772/568dbbe1cbfe/nihms-696565-f0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e56d/4480772/e8f5d6cc0932/nihms-696565-f0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e56d/4480772/cf22b000ae59/nihms-696565-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e56d/4480772/9fe4dee34862/nihms-696565-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e56d/4480772/2be01a1110ff/nihms-696565-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e56d/4480772/3942fe502db2/nihms-696565-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e56d/4480772/5c01b801a575/nihms-696565-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e56d/4480772/44515176487b/nihms-696565-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e56d/4480772/88d5a6a107ec/nihms-696565-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e56d/4480772/2dfc64ac1202/nihms-696565-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e56d/4480772/0f86d5ba369e/nihms-696565-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e56d/4480772/568dbbe1cbfe/nihms-696565-f0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e56d/4480772/e8f5d6cc0932/nihms-696565-f0011.jpg

相似文献

1
Docking studies on isoform-specific inhibition of phosphoinositide-3-kinases.针对磷酸肌醇 3-激酶同工型特异性抑制的对接研究。
J Chem Inf Model. 2010 Oct 25;50(10):1887-98. doi: 10.1021/ci1002679.
2
Binding selectivity studies of phosphoinositide 3-kinases using free energy calculations.利用自由能计算研究磷酸肌醇 3-激酶的结合选择性。
J Chem Inf Model. 2012 Dec 21;52(12):3213-24. doi: 10.1021/ci3003057. Epub 2012 Nov 30.
3
Combining properties of different classes of PI3Kα inhibitors to understand the molecular features that confer selectivity.结合不同类别的PI3Kα抑制剂的特性,以了解赋予选择性的分子特征。
Biochem J. 2017 Jun 26;474(13):2261-2276. doi: 10.1042/BCJ20161098.
4
N-Phenyl-4-hydroxy-2-quinolone-3-carboxamides as selective inhibitors of mutant H1047R phosphoinositide-3-kinase (PI3Kα).N- 苯基-4-羟基-2-喹诺酮-3-甲酰胺作为突变型 H1047R 磷酸肌醇-3-激酶(PI3Kα)的选择性抑制剂。
Bioorg Med Chem. 2012 Dec 15;20(24):7175-83. doi: 10.1016/j.bmc.2012.09.059. Epub 2012 Oct 12.
5
Exploring a non-ATP pocket for potential allosteric modulation of PI3Kα.探索用于PI3Kα变构调节的非ATP口袋。
J Phys Chem B. 2015 Jan 22;119(3):1002-16. doi: 10.1021/jp506423e. Epub 2014 Dec 3.
6
Biophysical and Structural Characterization of Novel RAS-Binding Domains (RBDs) of PI3Kα and PI3Kγ.新型 PI3Kα 和 PI3Kγ 的 RAS 结合结构域(RBD)的生物物理和结构特征。
J Mol Biol. 2021 Apr 16;433(8):166838. doi: 10.1016/j.jmb.2021.166838. Epub 2021 Feb 1.
7
Definition of the binding mode of phosphoinositide 3-kinase α-selective inhibitor A-66S through molecular dynamics simulation.通过分子动力学模拟对磷酸肌醇3-激酶α选择性抑制剂A-66S结合模式的定义
J Mol Model. 2014 Apr;20(4):2166. doi: 10.1007/s00894-014-2166-z. Epub 2014 Mar 16.
8
Biological evaluation and docking studies of recently identified inhibitors of phosphoinositide-3-kinases.新近鉴定的磷酸肌醇-3-激酶抑制剂的生物学评估和对接研究。
Bioorg Med Chem Lett. 2012 Jan 15;22(2):876-80. doi: 10.1016/j.bmcl.2011.12.044. Epub 2011 Dec 13.
9
Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein.发现选择性抑制 H1047R PI3Kα 突变蛋白的吡啶并嘧啶酮。
J Med Chem. 2024 Mar 28;67(6):4936-4949. doi: 10.1021/acs.jmedchem.4c00078. Epub 2024 Mar 13.
10
Comparative molecular dynamics analyses on PIK3CA hotspot mutations with PI3Kα specific inhibitors and ATP.使用PI3Kα特异性抑制剂和ATP对PIK3CA热点突变进行比较分子动力学分析。
Comput Biol Chem. 2022 Aug;99:107726. doi: 10.1016/j.compbiolchem.2022.107726. Epub 2022 Jul 8.

引用本文的文献

1
Exploring Carboxamide Derivatives as Promising Anticancer Agents: Design, In Vitro Evaluation, and Mechanistic Insights.探索羧酰胺衍生物作为有前景的抗癌药物:设计、体外评估及作用机制洞察
Int J Mol Sci. 2025 Jun 19;26(12):5903. doi: 10.3390/ijms26125903.
2
Quinolone Derivatives as Anticancer Agents: Importance in Medicinal Chemistry.喹诺酮衍生物作为抗癌剂:在药物化学中的重要性。
Curr Top Med Chem. 2024;24(13):1134-1157. doi: 10.2174/0115680266300736240403075307.
3
Targeting BRD4 and PI3K signaling pathways for the treatment of medulloblastoma.

本文引用的文献

1
Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin.强效PI3K和雷帕霉素哺乳动物靶点抑制剂GSK2126458的发现
ACS Med Chem Lett. 2010 Jan 19;1(1):39-43. doi: 10.1021/ml900028r. eCollection 2010 Apr 8.
2
28th Annual JPMorgan Healthcare Conference--Exelixis and Nektar Therapeutics.第28届摩根大通医疗保健会议——Exelixis公司和Nektar Therapeutics公司
IDrugs. 2010 Mar;13(3):139-41.
3
Pharmacophore modeling and 3D-QSAR analysis of phosphoinositide 3-kinase p110alpha inhibitors.磷酸肌醇 3-激酶 p110alpha 抑制剂的药效团建模和 3D-QSAR 分析。
针对脑桥小脑胶质瘤的 BRD4 和 PI3K 信号通路治疗。
J Control Release. 2023 Feb;354:80-90. doi: 10.1016/j.jconrel.2022.12.055. Epub 2023 Jan 5.
4
Comparative Anticancer Potentials of Taxifolin and Quercetin Methylated Derivatives against HCT-116 Cell Lines: Effects of -Methylation on Taxifolin and Quercetin as Preliminary Natural Leads.紫杉叶素和槲皮素甲基化衍生物对HCT-116细胞系的抗癌潜力比较:甲基化对紫杉叶素和槲皮素作为初步天然先导物的影响
ACS Omega. 2022 Dec 7;7(50):46629-46639. doi: 10.1021/acsomega.2c05565. eCollection 2022 Dec 20.
5
Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment.用于肿瘤治疗的双PI3K/mTOR抑制剂的最新进展
Front Pharmacol. 2022 May 9;13:875372. doi: 10.3389/fphar.2022.875372. eCollection 2022.
6
Molecular docking of phenolic compounds and screening of antioxidant and antidiabetic potential of ethanolic leaves extract from Qassim region, Saudi Arabia.沙特阿拉伯卡西姆地区乙醇叶提取物中酚类化合物的分子对接及其抗氧化和抗糖尿病潜力的筛选
Saudi J Biol Sci. 2022 Feb;29(2):854-859. doi: 10.1016/j.sjbs.2021.10.021. Epub 2021 Oct 13.
7
Molecular insight into isoform specific inhibition of PI3K-α and PKC-η with dietary agents through an ensemble pharmacophore and docking studies.通过集合药效基团和对接研究,了解膳食因子对 PI3K-α 和 PKC-η 异构体特异性抑制的分子机制。
Sci Rep. 2021 Jun 9;11(1):12150. doi: 10.1038/s41598-021-90287-3.
8
-Phenyl-6-Chloro-4-Hydroxy-2-Quinolone-3-CarboxAmides: Molecular Docking, Synthesis, and Biological Investigation as Anticancer Agents.苯基-6-氯-4-羟基-2-喹诺酮-3-羧酰胺:作为抗癌剂的分子对接、合成及生物研究。
Molecules. 2020 Dec 25;26(1):73. doi: 10.3390/molecules26010073.
9
Molecular Modeling, Synthesis and Biological Evaluation of -Phenyl-4-Hydroxy-6-Methyl-2-Quinolone-3-CarboxAmides as Anticancer Agents.基于 - 苯基 -4- 羟基 -6- 甲基 -2- 喹啉酮 -3- 甲酰胺的抗癌剂的分子建模、合成及生物学评价。
Molecules. 2020 Nov 16;25(22):5348. doi: 10.3390/molecules25225348.
10
Ligand-based design of GLUT inhibitors as potential antitumor agents.基于配体的 GLUT 抑制剂设计作为潜在的抗肿瘤药物。
Bioorg Med Chem. 2020 Apr 1;28(7):115395. doi: 10.1016/j.bmc.2020.115395. Epub 2020 Feb 18.
J Mol Model. 2010 Sep;16(9):1449-60. doi: 10.1007/s00894-010-0659-y. Epub 2010 Feb 19.
4
Class I phospho-inositide-3-kinases (PI3Ks) isoform-specific inhibition study by the combination of docking and molecular dynamics simulation.通过对接和分子动力学模拟相结合研究 I 类磷酸肌醇-3-激酶(PI3Ks)同工型特异性抑制作用。
J Chem Inf Model. 2010 Jan;50(1):136-45. doi: 10.1021/ci900175n.
5
A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane.一种常见的激酶结构域突变,改变了 PI3Kalpha 与膜之间的相互作用。
Proc Natl Acad Sci U S A. 2009 Oct 6;106(40):16996-7001. doi: 10.1073/pnas.0908444106. Epub 2009 Sep 23.
6
ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines.哺乳动物雷帕霉素靶蛋白的 ATP 竞争性抑制剂:高活性和高选择性的吡唑并嘧啶的设计与合成。
J Med Chem. 2009 Aug 27;52(16):5013-6. doi: 10.1021/jm900851f.
7
Targeting the phosphoinositide 3-kinase pathway in cancer.靶向癌症中的磷酸肌醇3-激酶通路。
Nat Rev Drug Discov. 2009 Aug;8(8):627-44. doi: 10.1038/nrd2926.
8
Molecular basis of Pirh2-mediated p53 ubiquitylation.Pirh2介导的p53泛素化的分子基础。
Nat Struct Mol Biol. 2008 Dec;15(12):1334-42. doi: 10.1038/nsmb.1521. Epub 2008 Nov 30.
9
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients.PI3KCA/PTEN失调导致转移性结直肠癌患者对西妥昔单抗反应受损。
Ann Oncol. 2009 Jan;20(1):84-90. doi: 10.1093/annonc/mdn541. Epub 2008 Jul 31.
10
Structural analysis of PI3-kinase isoforms: identification of residues enabling selective inhibition by small molecule ATP-competitive inhibitors.PI3激酶亚型的结构分析:确定能够被小分子ATP竞争性抑制剂选择性抑制的残基。
Arch Biochem Biophys. 2008 Sep 15;477(2):404-10. doi: 10.1016/j.abb.2008.06.024. Epub 2008 Jul 8.